REGN - REGENERON PHARMACEUTICALS, INC.

QQQ $ 429.07 $ 5.38 (1.28 %)

DIA $ 382.31 $ 3.34 (0.88 %)

SPY $ 505.01 $ 4.68 (0.94 %)

TLT $ 88.87 $ 0.38 (0.43 %)

GLD $ 213.12 $ -0.66 (-0.31 %)

Previous Close

$ 937.61

Open

$ 895.00

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 895.00 - $ 943.93

52 Week Range

$ 684.81 - $ 998.33

Volume

1,066,980

Average Volume

Market Cap

107.92B

Beta (5Y Monthly)

$ 0.54

PE Ratio (TTM)

$ 27.97

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-02-2024	03-31-2024	10-Q
2	02-05-2024	12-31-2023	10-K
3	11-02-2023	09-30-2023	10-Q
4	08-03-2023	06-30-2023	10-Q
5	05-04-2023	03-31-2023	10-Q
6	02-06-2023	12-31-2022	10-K
7	11-03-2022	09-30-2022	10-Q
8	08-03-2022	06-30-2022	10-Q
9	05-04-2022	03-31-2022	10-Q
10	02-07-2022	12-31-2021	10-K
11	11-04-2021	09-30-2021	10-Q
12	08-05-2021	06-30-2021	10-Q
13	05-06-2021	03-31-2021	10-Q
14	02-08-2021	12-31-2020	10-K
15	11-05-2020	09-30-2020	10-Q
16	08-05-2020	06-30-2020	10-Q
17	05-05-2020	03-31-2020	10-Q
18	02-07-2020	12-31-2019	10-K
19	11-05-2019	09-30-2019	10-Q
20	08-06-2019	06-30-2019	10-Q
21	05-07-2019	03-31-2019	10-Q
22	02-07-2019	12-31-2018	10-K
23	11-06-2018	09-30-2018	10-Q
24	08-02-2018	06-30-2018	10-Q
25	05-03-2018	03-31-2018	10-Q
26	02-08-2018	12-31-2017	10-K
27	11-08-2017	09-30-2017	10-Q
28	08-03-2017	06-30-2017	10-Q
29	05-04-2017	03-31-2017	10-Q
30	02-09-2017	12-31-2016	10-K
31	11-04-2016	09-30-2016	10-Q
32	08-04-2016	06-30-2016	10-Q
33	05-05-2016	03-31-2016	10-Q
34	02-11-2016	12-31-2015	10-K
35	11-04-2015	09-30-2015	10-Q
36	08-04-2015	06-30-2015	10-Q
37	05-07-2015	03-31-2015	10-Q
38	02-12-2015	12-31-2014	10-K
39	11-04-2014	09-30-2014	10-Q
40	08-05-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

regeneron-pharmaceuticals-targets-quality-weight-loss-in-latest-obesity-innovation

Regeneron Pharmaceuticals Targets Quality ...
05/02/2024 19:49:45

Regeneron Pharmaceuticals Q1 2024 earnings: EPS down 5%, sales miss; Eylea US sales drop 16%, Dupixent offsets. Oncology treatm...

wall-street-inches-up-after-powells-inflation-remarks-chipmakers-rebound-gold-crude-falter-whats-driving-markets-thursday

Wall Street Inches Up After Powell's Infla...
05/02/2024 17:37:33

U.S. stock markets surged during Thursday’s midday trading session in New York, with major averages all showing gains.

Industry Comparison: Evaluating Regeneron ...
05/02/2024 15:00:43

heres-how-much-you-would-have-made-owning-regeneron-pharmaceuticals-stock-in-the-last-20-years

Here's How Much You Would Have Made Owning...
05/02/2024 14:30:22

Regeneron Pharmaceuticals Q1 2024 Adj EPS ...
05/02/2024 10:31:29

Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $9.55 per share which missed the analyst consensus estim...

10-health-care-stocks-with-whale-alerts-in-todays-session

10 Health Care Stocks With Whale Alerts In...
04/30/2024 17:35:25

behind-the-scenes-of-regeneron-pharmaceuticalss-latest-options-trends

Behind the Scenes of Regeneron Pharmaceuti...
04/30/2024 14:31:36

Regeneron Presents Eye Treatment Results w...
04/29/2024 11:02:39

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the presentation of positive long-term results and subgroup analy...

abbvies-dermatitis-drug-shown-superior-to-sanofiregenerons-dupixent-in-head-to-head-study

AbbVie's Dermatitis Drug Shown 'Superior' ...
04/25/2024 17:58:29

AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficac...

Regeneron, Mammoth Partner To Pursue Next-...
04/25/2024 11:28:00

Under the terms of the agreement, Mammoth will receive $100 million inclusive of $95 million in equity investment at signing, a...

TD Cowen Maintains Buy on Regeneron Pharma...
04/24/2024 17:39:04

TD Cowen analyst Tyler Van Buren maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target fr...

Regeneron To Showcase Progress In Advancin...
04/24/2024 14:06:50

Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential ...

Regeneron To Present New And Updated Data ...
04/22/2024 21:56:09

ata from 10 abstracts, including six oral presentations, provide insight on Regeneron's approach to overcoming obstacles to...

Market Analysis: Regeneron Pharmaceuticals...
04/18/2024 15:00:49

amgenastrazenecas-asthma-drug-tezspire-vs-sanofiregenerons-blockbuster-dupixent---analyst-gives-his-pick

Amgen/AstraZeneca's Asthma Drug Tezspire V...
04/17/2024 18:39:45

Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent ...

if-you-invested-100-in-this-stock-20-years-ago-you-would-have-6700-today

If You Invested $100 In This Stock 20 Year...
04/17/2024 17:00:41

Cantor Fitzgerald Reiterates Neutral on Re...
04/17/2024 13:25:16

Cantor Fitzgerald analyst Olivia Brayer reiterates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and maintains $925...

Cantor Fitzgerald Reiterates Neutral on Re...
04/15/2024 18:29:25

Cantor Fitzgerald analyst Louise Chen reiterates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and maintains $925 p...

Breaking Down Regeneron Pharmaceuticals: 1...
04/12/2024 14:01:51

B of A Securities Maintains Underperform o...
04/12/2024 12:03:41

B of A Securities analyst Geoff Meacham maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Underperform and raises the...

Notes From The Street: 'FLASHBACK....Oil G...
01/13/2015 13:20:41